The Breast Cancer Screening and Timing of Breast MRI-Experience in a Genetic High-Risk Screening Clinic in a Comprehensive Cancer Center

被引:2
作者
Wang, Xia [1 ]
Chang, Maxine D. [1 ]
Lee, Marie Catherine [2 ]
Niell, Bethany L. [3 ]
机构
[1] H Lee Moffitt Canc Ctr & Res Inst, Dept Individualized Canc Management, GeneHome, Tampa, FL 33612 USA
[2] H Lee Moffitt Canc Ctr & Res Inst, Dept Breast Oncol, Tampa, FL 33612 USA
[3] H Lee Moffitt Canc Ctr & Res Inst, Dept Diagnost Imaging, Div Breast Imaging, Tampa, FL 33612 USA
关键词
breast MRI; mammography; high-risk screening; breast cancer; genetic predisposition; BRCA1; BRCA2; CDH1; PTEN; TP53; MUTATION CARRIERS; BRCA1; WOMEN; MAMMOGRAPHY; MASTECTOMY; REDUCTION; SURVEILLANCE; GUIDELINES; PATIENT; 1ST;
D O I
10.3390/curroncol29030171
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
For women with genetic risk of breast cancer, the addition of screening breast MRI to mammography has become a standard. The order and interval of annual imaging can be variable among providers. To evaluate the clinical implications related to the timing, we conducted a chart review on a cohort of women (N = 276) with high-risk (BRCA1, BRCA2, CDH1, PTEN and TP53) and moderate high-risk (ATM and CHEK2) predisposition to breast cancer in a 48-month follow up. The estimated MRI detection rate in the entire group is 1.75% (18 per 1000 MRI tests). For the high-risk group, the estimated rate is 2.98% (30 per 1000 MRI tests). Many women discovered their genetic risk at an age much older (average age of the high-risk group was 48 years) than the age recommended to initiate enhanced screening (age 20 to 25 years). In total, 4 of the 11 primary breast cancers detected were identified by screening MRI within the first month after initial visit, which were not detected by previous mammography, suggesting the benefit of initiating MRI immediately after the discovery of genetic risk. Breast screening findings for women with Lynch syndrome and neurofibromatosis type 1 were also included in this report.
引用
收藏
页码:2119 / 2131
页数:13
相关论文
共 26 条
  • [1] Evaluation of breast cancer risk assessment packages in the family history evaluation and screening programme
    Amir, E
    Evans, DG
    Shenton, A
    Lalloo, F
    Moran, A
    Boggis, C
    Wilson, M
    Howell, A
    [J]. JOURNAL OF MEDICAL GENETICS, 2003, 40 (11): : 807 - 814
  • [2] Effectiveness of breast cancer surveillance in BRCA1/2 gene mutation carriers and women with high familial risk
    Brekelmans, CTM
    Seynaeve, C
    Bartels, CCM
    Tilanus-Linthorst, MMA
    Meijers-Heijboer, EJ
    Crepin, CMG
    van Geel, AN
    Menke, M
    Verhoog, LC
    van den Ouweland, A
    Obdeijn, IM
    Klijn, JGM
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (04) : 924 - 930
  • [3] Risk-reducing mastectomy for the prevention of primary breast cancer
    Carbine, Nora E.
    Lostumbo, Liz
    Wallace, Judi
    Ko, Henry
    [J]. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2018, (04):
  • [4] Effectiveness of Screening With Annual Magnetic Resonance Imaging and Mammography: Results of the Initial Screen From the Ontario High Risk Breast Screening Program
    Chiarelli, Anna M.
    Prummel, Maegan V.
    Muradali, Derek
    Majpruz, Vicky
    Horgan, Meaghan
    Carroll, June C.
    Eisen, Andrea
    Meschino, Wendy S.
    Shumak, Rene S.
    Warner, Ellen
    Rabeneck, Linda
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (21) : 2224 - 2230
  • [5] Cost-effectiveness of alternating magnetic resonance imaging and digital mammography screening in BRCA1 and BRCA2 gene mutation carriers
    Chubiz, Jessica E. Cott
    Lee, Janie M.
    Gilmore, Michael E.
    Kong, Chung Y.
    Lowry, Kathryn P.
    Halpern, Elkan F.
    McMahon, Pamela M.
    Ryan, Paula D.
    Gazelle, G. Scott
    [J]. CANCER, 2013, 119 (06) : 1266 - 1276
  • [6] Use of Breast MRI Surveillance in Women at High Risk for Breast Cancer: A Single-Institutional Experience
    Elmore, Leisha
    Margenthaler, Julie A.
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2010, 17 : S263 - S267
  • [7] Comprehensive Breast Cancer Risk Assessment for CHEK2 and ATM Pathogenic Variant Carriers Incorporating a Polygenic Risk Score and the Tyrer-Cuzick Model
    Gallagher, Shannon
    Hughes, Elisha
    Kurian, Allison W.
    Domchek, Susan M.
    Garber, Judy
    Probst, Braden
    Morris, Brian
    Tshiaba, Placede
    Meek, Stephanie
    Rosenthal, Eric
    Roa, Benjamin
    Slavin, Thomas P.
    Wagner, Susanne
    Weitzel, Jeffrey
    Gutin, Alexander
    Lanchbury, Jerry S.
    Robson, Mark
    [J]. JCO PRECISION ONCOLOGY, 2021, 5 : 1073 - 1081
  • [8] Mastectomy trends for early-stage breast cancer: A report from the EUSOMA multi-institutional European database
    Garcia-Etienne, Carlos A.
    Tomatis, Mariano
    Heil, Joerg
    Friedrichs, Kay
    Kreienberg, Rolf
    Denk, Andreas
    Kiechle, Marion
    Lorenz-Salehi, Fatemeh
    Kimmig, Rainer
    Emons, Guenter
    Danaei, Mahmoud
    Heyl, Volker
    Heindrichs, Uwe
    Rageth, Christoph J.
    Janni, Wolfgang
    Marotti, Lorenza
    del Turco, Marco Rosselli
    Ponti, Antonio
    [J]. EUROPEAN JOURNAL OF CANCER, 2012, 48 (13) : 1947 - 1956
  • [9] Hereditary Diffuse Gastric Cancer Syndrome CDH1 Mutations and Beyond
    Hansford, Samantha
    Kaurah, Pardeep
    Li-Chang, Hector
    Woo, Michelle
    Senz, Janine
    Pinheiro, Hugo
    Schrader, Kasmintan A.
    Schaeffer, David F.
    Shumansky, Karey
    Zogopoulos, George
    Santos, Teresa Almeida
    Claro, Isabel
    Carvalho, Joana
    Nielsen, Cydney
    Padilla, Sarah
    Lum, Amy
    Talhouk, Aline
    Baker-Lange, Katie
    Richardson, Sue
    Lewis, Ivy
    Lindor, Noralane M.
    Pennell, Erin
    MacMillan, Andree
    Fernandez, Bridget
    Keller, Gisella
    Lynch, Henry
    Shah, Sohrab P.
    Guilford, Parry
    Gallinger, Steven
    Corso, Giovanni
    Roviello, Franco
    Caldas, Carlos
    Oliveira, Carla
    Pharoah, Paul D. P.
    Huntsman, David G.
    [J]. JAMA ONCOLOGY, 2015, 1 (01) : 23 - 32
  • [10] Substantial breast cancer risk reduction and potential survival benefit after bilateral mastectomy when compared with surveillance in healthy BRCA1 and BRCA2 mutation carriers: a prospective analysis
    Heemskerk-Gerritsen, B. A. M.
    Menke-Pluijmers, M. B. E.
    Jager, A.
    Tilanus-Linthorst, M. M. A.
    Koppert, L. B.
    Obdeijn, I. M. A.
    van Deurzen, C. H. M.
    Collee, J. M.
    Seynaeve, C.
    Hooning, M. J.
    [J]. ANNALS OF ONCOLOGY, 2013, 24 (08) : 2029 - 2035